Antiviral Activity, Safety, and Tolerability of Multiple Ascending Doses of Elbasvir or Grazoprevir in Participants Infected With Hepatitis C Virus Genotype-1 or -3

Purpose: Elbasvir (MK-8742) and grazoprevir (MK-5172; Merck & Co, Inc, Kenilworth, New Jersey) are hepatitis C virus (HCV)-specific inhibitors of the nonstructural protein 5A phosphoprotein and the nonstructural protein 3/4A protease, respectively. The aims of these studies were to evaluate the antiviral activity and safety of different doses of elbasvir or grazoprevir each administered as monotherapy to participants infected with either HCV genotype (GT) 1 or GT3. Methods: These 2 double-blind, randomized, placebo-controlled, sequential-panel, multiple ascending dose studies were conducted to assess the safety and pharmacodynamics of 5 days of once-daily elbasvir or 7 days of once-daily grazoprevir in adult male participants chronically infected with either HCV GT1 or GT3. Findings: Oral administration of elbasvir or grazoprevir once daily exhibited potent antiviral activity in participants with chronic GT1 or GT3 HCV infections. HCV RNA levels declined rapidly (within 1 day for elbasvir and 2 days for grazoprevir). At 50 mg of elbasvir once daily, the mean maximum reductions in HCV RNA from baseline were 5.21, 4.17, and 3.12 log10 IU/mL for GT1b-, GT1a-, and GT3-infected participants, respectively. At 100 mg of grazoprevir once daily, the mean maximum reductions in HCV RNA from baseline were 4.74 and 2.64 log10 IU/mL for GT1- and GT3-infected participants. Implications: The results in the elbasvir monotherapy study showed that 10 to 50 mg of elbasvir was associated with a rapid decline in HCV viral load; the results in the grazoprevir monotherapy study suggest that doses of 50 mg of grazoprevir and higher are on the maximum response plateau of the dose–response curve for GT1-infected participants. The results of these proof-of-concept studies provided preliminary data for the selection of the dosages of elbasvir and grazoprevir to test in Phase II and III clinical studies. identifiers: NCT00998985 (Protocol 5172-004) and NCT01532973 (Protocol 8742-002). © 2018 Elsevier HS Journals, Inc.

Yeh W.W.1 , Fraser I.P.1, 8 , Jumes P.1 , Petry A.1, 9 , Lepeleire I.D.2 , Robberechts M.2 , Reitmann C.1, 10 , Van Dyck K. , Huang X.1, 11 , Guo Z.1 , Panebianco D.1 , Nachbar R.B.1, 12 , O'Mara E.1, 13 , Wagner J.A.1, 14 , Butterton J.R.1 , Dutko F.J.1 , Moiseev V. 3 , Kobalava Z. 3 , Hüser A.4 , Visan S.5 , Schwabe C.6 , Gane E.7 , Popa S.5 , Ghicavii N.5 , Uhle M.4 , Wagner F.4
Number of issue
  • 1 Merck & Co, Inc., Kenilworth, New Jersey, United States
  • 2 MSD, Brussels, Belgium
  • 3 Center of Applied Clinical Pharmacology at Russian Peoples’ Friendship University, Moscow, Russian Federation
  • 4 Charité Research Organisation GmbH, Berlin, Germany
  • 5 ARENSIA Exploratory Medicine, Republican Clinical HospitalChisinau, Moldova
  • 6 Auckland Clinical Studies, Auckland, New Zealand
  • 7 Auckland City Hospital, Auckland, New Zealand
  • 8 Abide Therapeutics, Inc., Princeton, New Jersey, United States
  • 9 Bristol-Myers Squibb, Wallingford, Connecticut, United States
  • 10 Novartis, East Hanover, New Jersey, United States
  • 11 Sanofi-Aventis, Bridgewater, New Jersey, United States
  • 12 Wolfram Research, Inc., Champaign, Illinois, United States
  • 13 PTC Therapeutics Inc., South Plainfield, New Jersey, United States
  • 14 Takeda Pharmaceuticals, Cambridge, Massachusetts, United States
elbasvir; genotype 1; genotype 3; grazoprevir; hepatitis C virus; monotherapy
Date of creation
Date of change
Short link